Ensysce Biosciences, Inc. (ENSC)Healthcare | Biotechnology | La Jolla, United States | NasdaqCM
0.40 USD
+0.00
(0.226%)
⇧
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 0.39 -0.01 (-0.007%) ⇩ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 5:30 a.m. EDT
The immediate outlook is clouded by severe technical weakness and a deteriorating business model. While the stock recently spiked nearly 50%, it remains trapped well below its 50-day moving average, indicating that the recent rally was likely a capitulation event rather than a reversal. The company is actively reviewing strategic alternatives, a stark admission that management sees limited organic growth prospects at current valuations. Fundamentally, the enterprise is in freefall: revenue has contracted by 15% year-over-year, profitability is deeply negative, and the balance sheet shows negative book value with significant cash burn. The price action confirms this structural decline, having lost virtually all its value over the past seven years with five consecutive years of negative returns. There is no dividend to provide income, and the statistical models offer no reliable guidance due to extreme volatility. This is a distressed biotech play with no clear path to recovery visible in the current data. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.155874 |
| MSTL | 0.177623 |
| AutoTheta | 0.384967 |
| AutoARIMA | 0.582307 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 19% |
| H-stat | 14.07 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 2.73 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.679 |
| Market Cap | 7,780,771 |
| Forward P/E | -8.00 |
| Profit Margins | -280.48% |
| Previous Name | Leisure Acquisition Corp. |
| Website | https://www.ensysce.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.80817306 |
| Address1 | 7,946 Ivanhoe Avenue |
| Address2 | Suite 201 |
| All Time High | 86,364.0 |
| All Time Low | 0.23 |
| Ask | 0.5027 |
| Ask Size | 2 |
| Average Analyst Rating | 0.0 - Strong Buy |
| Average Daily Volume10 Day | 3,146,040 |
| Average Daily Volume3 Month | 14,883,772 |
| Average Volume | 14,883,772 |
| Average Volume10Days | 3,146,040 |
| Bid | 0.286 |
| Bid Size | 2 |
| Book Value | -0.048 |
| City | La Jolla |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.3999 |
| Current Ratio | 0.7 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 0.4119 |
| Day Low | 0.385 |
| Display Name | Ensysce Biosciences |
| Earnings Call Timestamp End | 1,711,033,200 |
| Earnings Call Timestamp Start | 1,711,033,200 |
| Earnings Timestamp End | 1,755,201,600 |
| Earnings Timestamp Start | 1,755,201,600 |
| Ebitda Margins | 0.0 |
| Enterprise To Revenue | 1.549 |
| Enterprise Value | 6,971,774 |
| Eps Forward | -0.05 |
| Eps Trailing Twelve Months | -2.56 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.3227 |
| Fifty Day Average Change | 0.077199996 |
| Fifty Day Average Change Percent | 0.23923148 |
| Fifty Two Week Change Percent | -80.81731 |
| Fifty Two Week High | 2.75 |
| Fifty Two Week High Change | -2.3501 |
| Fifty Two Week High Change Percent | -0.85458183 |
| Fifty Two Week Low | 0.23 |
| Fifty Two Week Low Change | 0.16989999 |
| Fifty Two Week Low Change Percent | 0.73869556 |
| Fifty Two Week Range | 0.23 - 2.75 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,521,034,200,000 |
| Float Shares | 19,443,174 |
| Forward Eps | -0.05 |
| Forward P E | -7.9979997 |
| Free Cashflow | -4,498,445 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 8 |
| Fullday Change | 0.0009 |
| Fullday Change Percent | 0.225564 |
| Fullday Price | 0.3929 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | -1.30559 |
| Gross Profits | -5,876,142 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.04716 |
| Held Percent Institutions | 0.0465 |
| Implied Shares Outstanding | 19,456,794 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-07-02 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,733,443,200 |
| Last Split Factor | 1:15 |
| Long Business Summary | Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company's lead product candidate is PF614, a TAAP oxycodone prodrug candidate for the treatment of severe or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection. It is also developing PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for attention deficit hyperactivity disorder; and PF9001 to treat opioid use disorder. Ensysce Biosciences, Inc. was founded in 2003 and is based in La Jolla, California. |
| Long Name | Ensysce Biosciences, Inc. |
| Market | us_market |
| Market Cap | 7,780,771 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_51791423 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-08-28 |
| Net Income To Common | -12,623,900 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 7,846,925 |
| Number Of Analyst Opinions | 1 |
| Open | 0.4048 |
| Operating Cashflow | -8,855,395 |
| Operating Margins | -2.21279 |
| Payout Ratio | 0.0 |
| Phone | 858 263 4196 |
| Post Market Change | -0.0069999993 |
| Post Market Change Percent | -1.7504375 |
| Post Market Price | 0.3929 |
| Post Market Time | 1,787,959,805 |
| Prev Name | Leisure Acquisition Corp. |
| Previous Close | 0.399 |
| Price Hint | 4 |
| Price To Book | -8.331249 |
| Price To Sales Trailing12 Months | 1.728771 |
| Profit Margins | -2.80484 |
| Quick Ratio | 0.269 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 0.0 |
| Region | US |
| Regular Market Change | 0.0009 |
| Regular Market Change Percent | 0.225564 |
| Regular Market Day High | 0.4119 |
| Regular Market Day Low | 0.385 |
| Regular Market Day Range | 0.385 - 0.4119 |
| Regular Market Open | 0.4048 |
| Regular Market Previous Close | 0.399 |
| Regular Market Price | 0.3999 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 486,120 |
| Return On Assets | -1.85507 |
| Return On Equity | -12.95089 |
| Revenue Growth | -0.151 |
| Revenue Per Share | 0.679 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 19,456,794 |
| Shares Percent Shares Out | 0.0586 |
| Shares Short | 1,140,145 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 403,334 |
| Short Name | Ensysce Biosciences, Inc. |
| Short Percent Of Float | 0.0586 |
| Short Ratio | 0.03 |
| Source Interval | 15 |
| State | CA |
| Symbol | ENSC |
| Target High Price | 8.25 |
| Target Low Price | 8.25 |
| Target Mean Price | 8.25 |
| Target Median Price | 8.25 |
| Total Cash | 676,704 |
| Total Cash Per Share | 0.035 |
| Total Debt | 196,842 |
| Total Revenue | 4,500,753 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.56 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 0.64747 |
| Two Hundred Day Average Change | -0.24757001 |
| Two Hundred Day Average Change Percent | -0.38236523 |
| Type Disp | Equity |
| Volume | 486,120 |
| Website | https://www.ensysce.com |
| Zip | 92,037 |